FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022687098> ?p ?o ?g. }

• W2022687098 abstract "(range 9–53%) with a median OS of 11.0 months (range 5.3– 18.1 months). The advantages of capecitabine are well documented and include good efficacy, tolerability with minimal grade 3–4 toxicity, oral preparation, maintaining quality of life, and cost effectiveness [6]. Another commonly employed option is vinorelbine, which in anthracycline and taxane pretreated patients, yields response rates (RR) of 10–35% as a single agent and 25–61% in combinations with non-taxanes in anthracycline pretreated patients [7–17]. Newer agents, such as eribulin, have gained approval by the FDA and EMA in patients with prior anthracycline and taxane exposure. The Embrace trial (Eribulin to best physicians choice) in heavily pre-treated locally advanced or MBC patients revealed an ORR of 12.2 versus 4.7% (p = 0.002), a progression free survival (PFS) of 3.7 versus 2.2 months (hazard ratio (HR) = 0.87, 95% confidence interval (CI) = 0.71–1.05, p = 0.137) and an OS of 13.1 versus 10.6 months (HR 0.81, 95% CI = 0.61–0.99, p = 0.041) with a tolerable toxicity profile [18]. Additional agents include nab-paclitaxel, which in phase II trials produced RR of 15% in anthracycline and taxane pretreated patients and ixabepilone in combination with capecitabine [19, 20]. A further alternative may arise from the ongoing BEACON trial, a phase III, open-label, randomized, multicenter study of pegylated irinotecan versus physician’s choice in 840 MBC patients pre-treated with anthracycline, taxane, and capecitabine in the adjuvant or metastatic setting [21]. In the current study of MMC and vinorelbine, 65% of patients were pre-treated with anthracyclines and taxanes, but it is unclear how these patients are positioned within the Pivot et al. classifications. This notwithstanding, the ORR was 26% with a median PFS of 5.0 months (95% CI = 3.6–6.8), comparable to other agents approved for this setting. We assume HER2 negativity though this is not described in the text, but alluded to in the conclusion. In developed countries nearly 30% of women with early stage breast cancer will eventually develop metastatic breast cancer (MBC), however, recent reports have demonstrated improvements in median survival mainly due to progresses made in treatment options [1, 2]. The therapeutic management of these women is multifaceted, encompassing many issues including tumor factors (i.e., aggression of disease, tumor burden, sites of disease, estrogen receptor, and HER2 status), previous treatment factors (i.e., use of and responsiveness to prior therapies, and associated toxicities) and last but not least patient factors (i.e., menopausal status, performance status, comorbidities, psychological concerns, and patient preferences). The phase II trial of mitomycin (MMC) and vinorelbine in patients with MBC pretreated with anthracycline and/or taxane, which appears in this month’s issue of Onkologie [3], successfully focuses attention on the need for effective second and third-line regimens once anthracyclines and taxanes fail. The concept of anthracycline/taxane resistance is complicated by an assortment of patient populations and definitions in the clinical literature. Thus, Pivot et al. [4] put forward a series of definitions for anthracycline resistance applicable to other chemotherapeutics. These are associated with a statistically significant difference in survival from the date of progression with the median overall survival (OS) being 5 months for primary and secondary resistance, 9 months for progressive disease (PD) within 6 months after the last dose of anthracycline and 11 months for PD between 6 and 12 months after the last dose of anthracycline, clearly signaling the need for clarity of definitions in clinical trials of this nature. Therapeutically, in this setting, capecitabine is approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) and was endorsed by the 1st international consensus guidelines for advanced breast cancer (ABC1) [5]. It thus represents the international standard of care. A systematic review of 28 single-agent capecitabine trials revealed a median overall response rate (ORR) of 28%" @default.
• W2022687098 created "2016-06-24" @default.
• W2022687098 creator A5076844591 @default.
• W2022687098 creator A5081663693 @default.
• W2022687098 date "2012-01-01" @default.
• W2022687098 modified "2023-09-26" @default.
• W2022687098 title "Treatment Options in Anthracycline and/or Taxane Pretreated Patients with Metastatic Breast Cancer" @default.
• W2022687098 cites W1521419744 @default.
• W2022687098 cites W1755746957 @default.
• W2022687098 cites W1828283074 @default.
• W2022687098 cites W1841504999 @default.
• W2022687098 cites W2006297166 @default.
• W2022687098 cites W2015159040 @default.
• W2022687098 cites W2015294539 @default.
• W2022687098 cites W2037154980 @default.
• W2022687098 cites W2061070776 @default.
• W2022687098 cites W2066547081 @default.
• W2022687098 cites W2079296876 @default.
• W2022687098 cites W2102118972 @default.
• W2022687098 cites W2104126300 @default.
• W2022687098 cites W2110444464 @default.
• W2022687098 cites W2115428190 @default.
• W2022687098 cites W2115518818 @default.
• W2022687098 cites W2127152525 @default.
• W2022687098 cites W2133176934 @default.
• W2022687098 cites W2142890220 @default.
• W2022687098 cites W2143399650 @default.
• W2022687098 cites W2148206476 @default.
• W2022687098 cites W2163017141 @default.
• W2022687098 cites W2407658592 @default.
• W2022687098 cites W2127340468 @default.
• W2022687098 doi "https://doi.org/10.1159/000342209" @default.
• W2022687098 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23007143" @default.
• W2022687098 hasPublicationYear "2012" @default.
• W2022687098 type Work @default.
• W2022687098 sameAs 2022687098 @default.
• W2022687098 citedByCount "2" @default.
• W2022687098 countsByYear W20226870982014 @default.
• W2022687098 crossrefType "journal-article" @default.
• W2022687098 hasAuthorship W2022687098A5076844591 @default.
• W2022687098 hasAuthorship W2022687098A5081663693 @default.
• W2022687098 hasBestOaLocation W20226870981 @default.
• W2022687098 hasConcept C121608353 @default.
• W2022687098 hasConcept C126322002 @default.
• W2022687098 hasConcept C143998085 @default.
• W2022687098 hasConcept C197934379 @default.
• W2022687098 hasConcept C207103383 @default.
• W2022687098 hasConcept C2775930923 @default.
• W2022687098 hasConcept C2776387010 @default.
• W2022687098 hasConcept C2776802502 @default.
• W2022687098 hasConcept C2777511904 @default.
• W2022687098 hasConcept C2777909004 @default.
• W2022687098 hasConcept C2778375690 @default.
• W2022687098 hasConcept C2779194965 @default.
• W2022687098 hasConcept C44249647 @default.
• W2022687098 hasConcept C526805850 @default.
• W2022687098 hasConcept C530470458 @default.
• W2022687098 hasConcept C71924100 @default.
• W2022687098 hasConceptScore W2022687098C121608353 @default.
• W2022687098 hasConceptScore W2022687098C126322002 @default.
• W2022687098 hasConceptScore W2022687098C143998085 @default.
• W2022687098 hasConceptScore W2022687098C197934379 @default.
• W2022687098 hasConceptScore W2022687098C207103383 @default.
• W2022687098 hasConceptScore W2022687098C2775930923 @default.
• W2022687098 hasConceptScore W2022687098C2776387010 @default.
• W2022687098 hasConceptScore W2022687098C2776802502 @default.
• W2022687098 hasConceptScore W2022687098C2777511904 @default.
• W2022687098 hasConceptScore W2022687098C2777909004 @default.
• W2022687098 hasConceptScore W2022687098C2778375690 @default.
• W2022687098 hasConceptScore W2022687098C2779194965 @default.
• W2022687098 hasConceptScore W2022687098C44249647 @default.
• W2022687098 hasConceptScore W2022687098C526805850 @default.
• W2022687098 hasConceptScore W2022687098C530470458 @default.
• W2022687098 hasConceptScore W2022687098C71924100 @default.
• W2022687098 hasLocation W20226870981 @default.
• W2022687098 hasLocation W20226870982 @default.
• W2022687098 hasOpenAccess W2022687098 @default.
• W2022687098 hasPrimaryLocation W20226870981 @default.
• W2022687098 hasRelatedWork W181195935 @default.
• W2022687098 hasRelatedWork W1976674836 @default.
• W2022687098 hasRelatedWork W2004505747 @default.
• W2022687098 hasRelatedWork W2026859784 @default.
• W2022687098 hasRelatedWork W2077296023 @default.
• W2022687098 hasRelatedWork W2133804515 @default.
• W2022687098 hasRelatedWork W2415253097 @default.
• W2022687098 hasRelatedWork W2415527985 @default.
• W2022687098 hasRelatedWork W2688575822 @default.
• W2022687098 hasRelatedWork W3143244965 @default.
• W2022687098 isParatext "false" @default.
• W2022687098 isRetracted "false" @default.
• W2022687098 magId "2022687098" @default.
• W2022687098 workType "article" @default.